Aqemia inks $140 million AI research deal with Sanofi

6 December 2023

Aqemia, a next-gen French pharmatech company leveraging artificial intelligence and quantum physics, has entered into a multi-year research collaboration with French pharma major Sanofi (Euronext: SAN).

The collaboration aims at discovering small molecule drug candidates across several therapeutic areas. Aqemia will leverage its unique platform that combines deep physics with generative AI at scale to identify the right chemical molecules for therapeutic targets of interest to Sanofi.

The deal builds on the companies' existing partnership to design and discover novel molecules for oncology that was first initiated at the end of 2020 and then extended in 2022.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK